The drug makes the body produce more IGF-1 — a hormone linked to growth and metabolism — which is exactly what you’d expect from a drug that stimulates growth hormone.

Scientific Claim

Tesamorelin (2 mg subcutaneous daily) causes a significant increase in insulin-like growth factor-1 (IGF-I) levels in HIV-infected adults on antiretroviral therapy with central fat accumulation over 6 months, consistent with its mechanism as a growth hormone-releasing factor.

Original Statement

“Insulin-like growth factor-1 increased (P < 0.001), but no change in glucose parameters was observed.”

From study:Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

The RCT design with a clear biomarker outcome and strong statistical significance (P < 0.001) supports definitive causal language. The claim aligns with the drug’s known pharmacology.

Evidence from Studies

Supporting (1)

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Randomized Controlled Trial

Human

2010 Mar

The study found that taking tesamorelin daily for 6 months made a key growth-related hormone (IGF-I) go up in HIV patients with belly fat, just like scientists expected it to.

Contradicting (0)

No contradicting evidence found

Source Study

Effects of Tesamorelin, a Growth Hormone–Releasing Factor, in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety Extension

Score: 81

DOI: 10.1097/QAI.0b013e3181cbdaff

Similar Assertions

The injection makes the body produce more of a natural growth-related hormone called IGF-1, which helps explain how it reduces belly fat.

98%

Tesamorelin boosts a key growth hormone-related protein in HIV patients without affecting their blood sugar levels.

86%

The drug shrinks the fat around the torso and makes the waist smaller, but doesn’t change the fat on the arms, legs, or just under the skin — meaning it targets only the dangerous internal fat.

84%

Denser under-the-skin fat in HIV patients on tesamorelin was linked to higher IGF-1 levels, a hormone involved in growth and metabolism, suggesting broader metabolic benefits.

83%

A hormone treatment called tesamorelin raises IGF-1 hormone levels more than a placebo in people with HIV at 2 weeks, 3 months, and 6 months of treatment.

83%